Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing.

TitleIdentification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing.
Publication TypeJournal Article
Year of Publication2013
AuthorsRobinson DR, Wu Y-M, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung Y-S, Chen C-L, Zhang L, Wang R, Su F, Iyer MK, Roychowdhury S, Siddiqui J, Pienta KJ, Kunju LP, Talpaz M, Mosquera JMiguel, Singer S, Schuetze SM, Antonescu CR, Chinnaiyan AM
JournalNat Genet
Volume45
Issue2
Pagination180-5
Date Published2013 Feb
ISSN1546-1718
KeywordsAdult, Base Sequence, Cell Proliferation, Cells, Cultured, Chromatin Immunoprecipitation, DNA Mutational Analysis, Exome, Female, Fluorescent Antibody Technique, Gene Expression Regulation, Neoplastic, Gene Fusion, High-Throughput Nucleotide Sequencing, Humans, Immunoblotting, Luciferases, Models, Genetic, Molecular Sequence Data, Real-Time Polymerase Chain Reaction, Regulatory Elements, Transcriptional, Repressor Proteins, Reverse Transcriptase Polymerase Chain Reaction, Solitary Fibrous Tumors, STAT6 Transcription Factor, Transcriptome
Abstract

A 44-year old woman with recurrent solitary fibrous tumor (SFT)/hemangiopericytoma was enrolled in a clinical sequencing program including whole-exome and transcriptome sequencing. A gene fusion of the transcriptional repressor NAB2 with the transcriptional activator STAT6 was detected. Transcriptome sequencing of 27 additional SFTs identified the presence of a NAB2-STAT6 gene fusion in all tumors. Using RT-PCR and sequencing, we detected this fusion in all 51 SFTs, indicating high levels of recurrence. Expression of NAB2-STAT6 fusion proteins was confirmed in SFT, and the predicted fusion products harbor the early growth response (EGR)-binding domain of NAB2 fused to the activation domain of STAT6. Overexpression of the NAB2-STAT6 gene fusion induced proliferation in cultured cells and activated the expression of EGR-responsive genes. These studies establish NAB2-STAT6 as the defining driver mutation of SFT and provide an example of how neoplasia can be initiated by converting a transcriptional repressor of mitogenic pathways into a transcriptional activator.

DOI10.1038/ng.2509
Alternate JournalNat Genet
PubMed ID23313952
Grant List5 P30 CA46592 / CA / NCI NIH HHS / United States
P01 CA047179-15A2 / CA / NCI NIH HHS / United States
P50 CA 140146-01 / CA / NCI NIH HHS / United States
Related Faculty: 
Juan Miguel Mosquera, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700